49th week of 2009 patent applcation highlights part 50 |
Patent application number | Title | Published |
20090298073 | Kidney Toxicity Biomarkers - Novel biomarkers for kidney toxicity. Said biomarkers may be useful for optimization of lead compounds, or in safety assessment. | 2009-12-03 |
20090298074 | Modulators of ELOVL5 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of ELOVL5 and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 2009-12-03 |
20090298075 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING - Compositions and methods for nucleic acid sequencing include template constructs that comprise double stranded portions in a partially or completely contiguous constructs, to provide for redundant sequence determination through one or both of sequencing sense and antisense strands, and iteratively sequencing the entire construct multiple times. Additional sequence components are also optionally included within such template constructs. Methods are also provided for the use and preparation of these constructs as well as sequencing compositions for their application. | 2009-12-03 |
20090298076 | DETECTION OF SALMONELLA BY REAL-TIME MULTIPLEX PCR - The invention relates to the detection of | 2009-12-03 |
20090298077 | ASSAY FOR MEASUREMENT OF APURINIC/APYRIMIDINIC (AP) SITES AND FOR SCREENING AP-SITE REACTIVE COMPOUNDS - A method of detecting abasic (AP) sites in DNA from a subject includes isolating a sample of DNA from a subject under examination, contacting the DNA with a fluorescent aldehyde reactive probe (FARP), and detecting FARP labeled AP sites in the DNA sample. | 2009-12-03 |
20090298078 | METHOD FOR THE DETECTION OF AN ACTIVATION OF THE IMMUNE SYSTEM OR THE EXTENT OF CELL DEATH - The present invention relates to a method for the detection of an activation of the immune system, preferably in the sense of an NET formation, or the extent of cell death in a non-tumorous tissue or in a body fluid, wherein free DNA is measured in a sample from an individual. Furthermore, the invention relates to a method for the production of a kit for the detection of an activation of the immune system or the extent of cell death in an individual, comprising the packaging of a fluorescent dye and a DNA standard in at least one container. | 2009-12-03 |
20090298079 | HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF - Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor. | 2009-12-03 |
20090298080 | METHODS AND REAGENTS FOR DETECTING CpG METHYLATION WITH A METHYL CpG BINDING PROTEIN (MBP) - The present invention provides a simple and sensitive technology for the detection of CpG methylation in DNA without chemical modification of sample DNA by bisulfite treatment or PCR amplification. Signal generation is based on an Abscription (Abortive Transcription) technology in which DNA signal generators called Abortive Promoter Cassettes (APCs) are bound to target mCpG sites via mCpG target specific probes based on methyl binding polypeptides or methyl binding domains thereof. RNA polymerase produces uniform, short RNA molecules from synthetic promoters in APCs as signals of the presence of methylated CpGs. Detection of CpG methylation and hypermethylation of DNA targets such as CpG islands provides a convenient means for detecting and monitoring cancer in a subject. | 2009-12-03 |
20090298081 | METHODS OF TREATMENT UTILIZING BINDING PROTEINS OF THE INTERLEUKIN-21 RECEPTOR - The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders. | 2009-12-03 |
20090298082 | BIOMARKER PANELS FOR PREDICTING PROSTATE CANCER OUTCOMES - This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radial prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided. | 2009-12-03 |
20090298083 | Phospho-Specific Anti-Pax3 Antibodies - Pax3, a member of the paired class homeodomain family of transcription factors and an essential protein for early skeletal muscle development, was shown to be phosphorylated in proliferating mouse primary myoblasts. Furthermore, Ser205, Ser201 and Ser209 were identified as the only sites of phosphorylation on Pax3 in proliferating mouse primary myoblasts. Phosphorylation of Ser205 was shown to be required for the efficient phosphorylation of Ser201 and/or Ser209. Site-specific antibodies were made to each of these three sites when phosphorylated. These three sites are also present and phosphorylated in the Pax3-FOXO1 fusion protein, and phosphorylation of these sites may play a role in ARMS. Thus, these new antibodies may be used in studying the regulation of nerve and muscle development and differentiation and in finding therapeutic solutions for certain disorders, including Waardenburg syndrome and childhood solid muscle tumor alveolar rhabdomyosarcoma (ARMS). | 2009-12-03 |
20090298084 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF IRINOTECAN - The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample. | 2009-12-03 |
20090298085 | Detection of Extracellular Tumor-Associated Nucleic Acid in Blood Plasma or Serum Using Nucleic Acid Amplification Assays - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals. | 2009-12-03 |
20090298086 | PLANT FARNESYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a farnesyltransferase subunit. The invention also relates to the construction of a chimeric gene encoding all or a portion of the farnesyltransferase subunit, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the farnesyltransferase subunit in a transformed host cell. | 2009-12-03 |
20090298087 | METHODS AND PROBES FOR THE DETECTION OF CANCER - Probe sets and methods of using probes and probe sets for the detection of cancer are described. Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if cancer cells are present the sample. Also included are methods of selecting a combination of probes for the detection of cancer. | 2009-12-03 |
20090298088 | CLEAVABLE CATALYTIC BINDING AND DETECTION SYSTEM - The present invention provides a detection reagent for detection of the presence of a substance of interest in a sample. The detection reagent comprises a binding portion, a linking portion, and a catalytic portion. The linking portion comprises a cleavage site for cleavage of the binding portion from the catalytic portion. According to the method, the detection reagent is caused to bind to the substance of interest. The bound reagent is then cleaved by breaking of a bond in the linking portion. Upon cleavage, the catalytic portion is removed from the binding reaction mixture and caused to catalyze a reaction that produces a detectable product. | 2009-12-03 |
20090298089 | Novel method for detecting and analyzing protein interactions in vivo - The invention relates to various methods of detecting and analyzing protein interactions in a cell, which methods involve the appearance of a specific protein interaction being converted to a permanent detection signal by means of providing, in a manner dependent on said protein interaction, a recombinase activity or protease activity. | 2009-12-03 |
20090298090 | METHODS TO MEASURE IMMUNOSUPPRESSIVE TACROLIMUS, SIROLIMUS, AND CYCLOSPORIN A COMPLEXES IN A BLOOD SAMPLE - The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems. | 2009-12-03 |
20090298091 | Modulation of T Cell Recruitment - The instant invention is based, at least in part, on the discovery that T-bet controls ThI cell recruitment to sites of inflammation. This invention pertains to, inter alia, methods of identifying agents that modulate the effects of T-bet on the recruitment of T cells to sites of inflammation by modulating P-selectin-mediated T cell rolling and/or stable adherence of a T cell to a vascular endothelial cell, as well as methods of use therefore. | 2009-12-03 |
20090298092 | ANALYTICAL SYSTEM, AND ANALYTICAL METHOD AND FLOW STRUCTURE THEREOF - An analytical system includes a working fluid, a uniform dividing unit and a separating unit. The working fluid includes a first component and a second component with different characteristics. The uniform dividing unit is utilized to uniformly divide the working fluid and relatively rotated with respect to a reference axis. Under a capillarity force as well as the result of Coriolis force and siphon force, the first component can be separated from the second component by the separating unit. | 2009-12-03 |
20090298093 | Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways - The invention discloses nearly 300 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human ATM/ATR kinase signaling pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection, profiling and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: DNA repair proteins, Adaptor/Scaffold proteins, Cell cycle regulation proteins, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, DNA binding proteins, DNA replication proteins, Kinases, Disease associated proteins proteins, Methyltransferase, Ubiquitin conjugating proteins, Proteases, Phosphatases, and Transcription proteins. | 2009-12-03 |
20090298094 | METHOD OF ANALYZING BIOCHEMICAL - A method of highly sensitive and quantitative luminescent analysis with the use of a detection device using a micro-channel and carrying a molecule which is capable of capturing a substance to be detected and bonded to a solid phase. A biochemical to be detected is captured in a channel-type device having a probe bonded to a solid phase. After labeling for luminescence, a luminescent reagent is flown thereto and the luminescence in the vicinity of the probe is optically detected. | 2009-12-03 |
20090298095 | Immortalization of cells including neuronal cells - The instant invention provides methods for immortalizing cells. The invention further provides immortalized cell lines, e.g., neuronal cell lines, and methods of using these cell lines in screening assays. | 2009-12-03 |
20090298096 | Interleukin-1 alpha ABS and methods of use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 2009-12-03 |
20090298097 | METHODS FOR THE DIAGNOSIS OF LUNG CANCER - The present invention is directed to new ways to diagnosis lung cancer, especially at an early clinical stage. In addition, prognosis and the monitoring of therapeutic agents or other treatments, for lung cancer patients, can be accomplished with the disclosed methods. The methods also find use in allowing the assessment by pre-clinical animal efficacy studies to screen for the useful of therapeutic agents for treating lung cancer. | 2009-12-03 |
20090298099 | Gonococcal Proteins and Nucleic Acids - The invention provides proteins from gonococcus ( | 2009-12-03 |
20090298100 | Monoclonal Antibody Against D-Dimer and Diagnosis Agent for Detecting D-Dimer, Crosslinked Fibrin and its Derivatives Containing D-Dimer by Using the Antibody - Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight crosslinked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and a method for manufacturing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnosis agent for screening and detecting in vivo D-dimer, and high molecular weight crosslinked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and crosslinked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin. | 2009-12-03 |
20090298101 | Blood C5a Levels as an Indicator of Rhinoconjunctivitis Severity - The present invention provides methods of determining the severity of rhinoconjunctivitis in a patient by determining the levels of C5a or C5a-desArg in the patient's blood, plasma or serum. | 2009-12-03 |
20090298102 | Cell Potency Assay - Cell potency assays for use with cell-based therapies, and specifically, with stem cell therapies, are provided. Cell potency assays for bone marrow cells, mobilized peripheral blood, and umbilical cord blood are provided. | 2009-12-03 |
20090298103 | Predicting hemostatic risk; dependence on plasma composition - Featured are methods for assessing hemostatic risk including the risk for ACS. Such methods include acquiring blood/plasma composition based on a biological sample obtained from a subject, determining parameters associated with blood clotting, simulating in silico blood clotting using the determined parameters and comparing the results of such simulation to a reference and to determine the hemostatic risk from said comparing. In further embodiments, such methods further include selecting a treatment regime or protocol based on the results of such comparing. In yet further embodiments, such methods further include assessing the efficacy of medicants, drugs and the like of a given treatment protocol such as by simulating in silico the application of such medicants, drugs and the like. | 2009-12-03 |
20090298104 | REFERENCE ELECTRODES HAVING AN EXTENDED LIFETIME FOR USE IN LONG TERM AMPEROMETRIC SENSORS - The present application provides Ag/AgCl based reference electrodes having an extended lifetime that are suitable for use in long term amperometric sensors. Electrochemical sensors equipped with reference electrodes described herein demonstrate considerable stability and extended lifetime in a variety of conditions. | 2009-12-03 |
20090298105 | RECONSTITUTED HISTONE METHYLTRANSFERASE COMPLEX AND METHODS OF IDENTIFYI NG MODULATORS THEREOF - The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided. | 2009-12-03 |
20090298106 | Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples - Systems and methods are provided for monitoring a immunosuppressant drug level and renal function, hepatic function, or a combination thereof in a patient, comprising obtaining a small volume blood sample from the patient; determining the level of at least one immunosuppressant drug in the small volume blood sample and determining the level of a second immunosuppressant drug or analyzing the renal function, the hepatic function, or a combination thereof in the patient. In some embodiments, the immunosuppressant drug levels are determined using a liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure. Also provided are kits for use in any of the systems and methods described herein. | 2009-12-03 |
20090298107 | METHODS FOR DIAGNOSING CHRONIC DIARRHEA THROUGH PROTEIN SECRETION ANALYSIS - Methods for diagnosing chronic diarrhea and other gastrointestinal conditions. In the methods, a sample of gastrointestinal secretions is obtained from a control group; or a group who has been diagnosed with either healthy gastrointestinal tracts or with a gastrointestinal condition, like chronic diarrhea. The control group samples are analyzed in any suitable manner to determine the levels of gastrointestinal secretions, including one or more cytokeratin I subtypes, cytokeratin II subtypes, antimicrobial proteins, mitochondria, and digestive enzymes. The results of the sample analysis is used to create a database containing profiles of normal and abnormal gastrointestinal secretions. As the database is created and specific secretion level abnormalities are identified, patients may be diagnosed with these abnormalities and be treated by adjusting the levels of specific secretions. Gastrointestinal samples from subsequent patients may be analyzed and compared with the database to determine which of the patients' secretion levels, if any, are abnormal. | 2009-12-03 |
20090298108 | Method for Identifying PDE11 Modulators - The invention relates to a novel GAF | 2009-12-03 |
20090298109 | METHOD FOR IDENTIFYING BPLP AND OPIORPHIN AGONISTS OR ANTAGONISTS - A method for in vitro functional characterization of Opiorphin derivatives by using highly selective biochemical assays. The method may employ an assay involving contacting an Opiorphin derivative with an enkephalin-inactivating ectopeptidase, such as neutral endopeptidase NEP (EC 3.4.24.11) or aminopeptidase AP-N (EC 3.4.11.2). This method provides a rapid and sensitive assay for measuring activity of these two membrane-anchored ectoenzymes when contacted with Opiorphin derivative by means of a selective fluorescence-based enzyme model. | 2009-12-03 |
20090298110 | Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase - This invention relates to the identification and characterization of racemases and definition of protein signatures of these racemases. More particularly, this invention relates to the identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs and more specifically SEQ ID NOS:1-4. This invention also relates to antibodies specific for the peptides and to immune complexes of these antibodies with the peptides. Further, the invention relates to methods and kits for detecting racemases using the nucleic acid molecules of the invention, as well as the peptides consisting of the motifs and antibodies to these peptides. | 2009-12-03 |
20090298111 | METHOD AND COMPOSITION FOR A PROTEIN TRANSDUCTION TECHNOLOGY AND ITS APPLICATIONS - A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein. | 2009-12-03 |
20090298112 | MOUSE MODEL AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY - Disclosed herein are methods of treating HIBM in a subject comprising identifying subject in need thereof, and administering to the subject a compound, or a pharmaceutically acceptable salt, ester, amide, glycol, peptidyl, or prodrug thereof, wherein the compound is a compound that is biosynthesized in a wild type individual along a biochemical pathway between glucose and sialic acid, inclusive. Also disclosed herein are vectors comprising a nucleic acid sequence that encodes a polypeptide having at least 80% sequence identity to the sequence set forth in SEQ ID NO:2, recombinant cells comprising these vectors, and recombinant animals comprising the cells. In addition, methods of identifying a compound having therapeutic effect for HIBM are disclosed. | 2009-12-03 |
20090298113 | EX VIVO HUMAN SKIN MODEL - The present invention relates to the use of an ex vivo human skin sample as a biological model, particularly for the assessment of pharmacological and cosmetic effects. | 2009-12-03 |
20090298114 | APPARATUS AND METHODS FOR IMAGING AND MODIFICATION OF BIOLOGICAL SAMPLES - This invention relates to enrichment of a biological sample comprising a plurality of cells to assist further analysis thereof. It provides a technique comprising the steps of: (a) providing a sample comprising a plurality of cells which include a photosensitive compound that can be induced by light irradiation to inactivate or kill at least part of the respective cell; (b) acquiring an image of at least a portion of the sample; (c) identifying cells of interest in the sample image; (d) selecting cells other than the cells identified in step (c); and (e) irradiating only those cells selected in step (d) with a light beam so as induce the photosensitive compound therein to inactivate or kill at least part of those cells, and thereby enrich the sample with respect to the cells of interest for further analysis. | 2009-12-03 |
20090298115 | Fluorescent Gold Nanocluster and Method for Forming the Same - The present invention discloses a fluorescent gold nanocluster, comprising: a dihydrolipoic acid ligand (DHLA) on the surface thereof, wherein the fluorescent gold nanocluster generates fluorescence by the interaction between the dihydrolipoic acid ligand and the nanocluster and the particle diameter of the fluorescent gold nanocluster is between 0.5 nm and 3 nm, wherein the wavelength of the emission fluorescence of the fluorescent gold nanocluster is between 400 nm and 1000 nm. In addition, the fluorescent gold nanocluster is used as bioprobes and/or applied in fluorescent biological label, clinical image as contrast medium, clinical detection, clinical trace, and clinical treatment etc. | 2009-12-03 |
20090298116 | CELL CULTURE APPARATUS HAVING DIFFERENT MICRO-WELL TOPOGRAPHY - A cell culture apparatus includes a substrate having formed therein a micro-well array, the micro-well array comprising a plurality of micro-wells. Each micro-well is defined by a curved surface which is concave. | 2009-12-03 |
20090298117 | METHODS FOR HETEROLOGOUS EXPRESSION OF SECONDARY METABOLITES - The invention provides a method for the heterologous expression of a secondary metabolite encoded by a biosynthetic pathway. Also provided is a method for introducing a large sized DNA molecule into the chromosome of a heterologous host using a transposable element. Novel myxochromide S derivatives are also provided. | 2009-12-03 |
20090298118 | Enzymatic Conversion of Oligopeptide Amides to Oligopeptide Alkylesters - The present invention relates to enzymatic oligopeptide synthesis in the N→C direction, in particular to a process for the preparation of an optionally N-protected oligopeptide C-terminal alkylester comprising the step of reacting the corresponding optionally N-protected oligopeptide C-terminal carboxyamide with an alkyl alcohol, preferably methanol, in the presence of a peptide amidase. The formed C-terminal alkylester can subsequently be used for the coupling with another amino acid residue or oligopeptide. Therefore, inventors have found a very advantageous process for the preparation of oligopeptides. | 2009-12-03 |
20090298119 | Genetically encoded coumarin amino acids - The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate the coumarin unnatural amino acid L-(7-hydroxycoumarin-4-yl)ethylglycine into proteins produced in eubacterial host cells such as | 2009-12-03 |
20090298120 | METHOD FOR EXPRESSING SIALYLATED GLYCOPROTEINS IN MAMMALIAN CELLS AND CELLS THEREOF - Methods and systems for producing glycoproteins having sialylated oligosaccharides are provided. The invention comprises the genetic engineered cells with a CMP-sialic acid transporter (CMP-SAT) gene so that the cells express the CMP-SAT protein or fragment thereof at an above endogenous levels. The increase in CMP-SAT expression allows for the increased transport of the CMP-sialic acid into the Golgi apparatus so as to obtain sialylation of glycoproteins at above endogenous levels. In particular, the methods and systems of the invention are useful for producing complex sialylated glycoproteins in mammalian cells of interest, for example Chinese Hamster Ovary (CHO) cells. | 2009-12-03 |
20090298121 | EXPRESSION OF SOLUBLE THERAPEUTIC PROTEINS - The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment. | 2009-12-03 |
20090298122 | Translational Elongation Factor Promoter From Pichia Pastoris And Method For Producing Recombinant Protein Using The Same - Disclosed are a | 2009-12-03 |
20090298123 | Novel Lipase Genes - New lipase enzymes (both nucleic acids and polypeptides) are provided. Compositions which include these polypeptides, proteins, nucleic acids, recombinant cells, as well as methods involving the enzymes, antibodies to the enzymes, and methods of using the enzymes are also provided. | 2009-12-03 |
20090298124 | Site-specific incorporation of redox active amino acids into proteins - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs. | 2009-12-03 |
20090298125 | HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES - The present invention relates to novel halohydrin dehalogenase polypeptides and the polynucleotides that encode them. These polypeptides are useful in the production of 4-substituted-3-butyric acid derivatives and vicinal cyano, hydroxyl substituted carboxylic acid esters. The invention also provides related vectors, host cells and methods. | 2009-12-03 |
20090298126 | Methods of increasing secretion of polypeptides having biological activity - The present invention relates to methods for producing a secreted polypeptide having biological activity, comprising: (a) transforming a fungal host cell with a fusion protein construct encoding a fusion protein, which comprises: (i) a first polynucleotide encoding a signal peptide; (ii) a second polynucleotide encoding at least a catalytic domain of an endoglucanase or a portion thereof; and (iii) a third polynucleotide encoding at least a catalytic domain of a polypeptide having biological activity; wherein the signal peptide and at least the catalytic domain of the endoglucanase increases secretion of the polypeptide having biological activity compared to the absence of at least the catalytic domain of the endoglucanase; (b) cultivating the transformed fungal host cell under conditions suitable for production of the fusion protein; and (c) recovering the fusion protein, a component thereof, or a combination thereof, having biological activity, from the cultivation medium. | 2009-12-03 |
20090298127 | METHOD FOR PRODUCING PURINE NUCLEOSIDES AND NUCLEOTIDES BY FERMENTATION USING A BACTERIUM BELONGING TO THE GENUS ESCHERICHIA OR BACILLUS - A method is provided for producing a purine nucleoside, such as inosine and guanosine, and a method for producing a 5′-purine nucleotide such as 5′-inosinic acid or 5′-guanylic acid, using a bacterium belonging to the either genus | 2009-12-03 |
20090298128 | Method for Amplifying Unknown DNA Sequence Adjacent to Known Sequence - The present invention relates to a method for amplifying an unknown nucleotide sequence adjacent to a known nucleotide sequence, which comprises the step of (a) performing a primary amplification of the unknown nucleotide sequence using a DNA walking annealing control primer (DW-ACP) and a first target specific primer (TSP) hybridizable with a site on the known nucleotide sequence; in which the step (a) comprises: (a-1) performing a first-stage amplification of the unknown nucleotide sequence at a first annealing temperature, using a first degenerate DW-ACP containing (i) a degenerate random nucleotide sequence to hybridize with the unknown nucleotide sequence and (ii) a hybridizing nucleotide sequence substantially complementary to a site on the unknown nucleotide sequence, wherein the first annealing temperature enables the first degenerate DW-ACP to function as a primer, whereby a first degenerate DW-ACP extension product is generated; and (a-2) performing a second-stage amplification of the amplification product generated from step (a-1) at a second annealing temperature which is higher than the first annealing temperature, using the first degenerate DW-ACP as used in the step (a-1) and the first TSP, under conditions in which each primer anneals the its target nucleotide sequence, whereby a primary amplification product is generated. | 2009-12-03 |
20090298129 | SYSTEMS AND METHODS FOR PROCESSING SAMPLES IN A CLOSED CONTAINER, AND RELATED DEVICES - A system and method for automated processing of nucleic acids and other samples includes a disposable container comprising a tray and a flexible barrier. The barrier is configured to seal with a top edge of the tray, providing a closed, aseptic work area within the sealed tray. A pipette head and/or other sample manipulation device can be attached to the inside of the barrier, and the barrier can include an interface for a robotic arm or other device. When the barrier is sealed over the tray, the barrier separates the contents of the tray from the robot or other manipulation device. The barrier can be flexible, and allow the robotic arm to move the pipette head throughout the work area of the tray. All samples, reagents, pipette tips and other tools or devices for processing nucleic acid samples may remain within the closed compartment provided by the container during processing. | 2009-12-03 |
20090298130 | LADDER ASSEMBLY AND SYSTEM FOR GENERATING DIVERSITY - The present invention provides novel methods of generating a nucleic acid molecule. In certain embodiments, a double stranded nucleic acid chunk is generated from a ladder complex comprising partially complementary oligonucleotides, which chunk is combined with a nucleic acid acceptor molecule. In certain embodiments, the assembled chunk/nucleic acid acceptor molecule complex may be propagated in vivo or in vitro. The present invention also provides improved systems for generating a plurality of nucleic acid molecules that differ at one or more nucleotide positions. In certain embodiments, the plurality of nucleic acid molecules encodes a polypeptide or portion of a polypeptide. | 2009-12-03 |
20090298131 | Non-Emulsion Methods And Masked Biomolecules - The present invention relates to methods and devices for amplifying nucleic acid, and, in particular, amplifying so as to generate products on a surface without the use of emulsions. In a preferred embodiment, a plurality of groups of amplified product are generated on the surface, each group positioned in different (typically predetermined) locations on said surface so as to create an array. | 2009-12-03 |
20090298132 | INTEGRATION OF SAMPLE STORAGE AND SAMPLE MANAGEMENT FOR LIFE SCIENCE - Compositions and methods are disclosed for automated storing, tracking, retrieving and analyzing biological samples, including dry storage at ambient temperatures of nucleic acids, proteins (including enzymes), and cells using a dissolvable dry storage matrix that permits recovery of biologically active materials. RFID-tagged biological sample storage devices featuring dissolvable or dissociable matrices are described for use as supports of biological samples, which matrices can be dried and subsequently rehydrated for sample recovery. Also disclosed are computer-implemented systems and methods for managing sample data. | 2009-12-03 |
20090298133 | De novo enzymatic production of nucleic acid molecules - The present invention is related to a method for the manufacture of a nucleic acid molecule comprising the following steps: a) providing a first at least partially double-stranded oligonucleotide, whereby the oligonucleotide comprises a first and a second single-stranded overhang, b) providing a second at least partially double-stranded oligonucleotide, whereby the oligonucleotide comprises a recognition site for a first type IIS restriction enzyme which cuts outside its recognition site, a modification allowing the oligonucleotide to be coupled to a surface and a single-stranded overhang, c) ligating the first oligonucleotide and the second oligonucleotide via the first single-stranded overhang of the first oligonucleotide and the single-stranded overhang of the second oligonucleotide, generating a first ligation product, whereby the first ligation product comprises a single-stranded overhang essentially corresponding to the second single-stranded overhang of the first oligonucleotide, d) cutting the first ligation product with the first type II restriction enzyme thus releasing an elongated first at least partially double-stranded oligonucleotide having a first and a second single-stranded overhang, whereby the first single-stranded overhang is generated through the cutting of the restriction enzyme and whereby the second single-stranded overhang corresponds essentially to the second single-stranded overhang of the first at least partially double-stranded oligonucleotide, preferably the at least partially double-stranded oligonucleotide of step (a), and a truncated second at least partially double-stranded oligonucleotide; e) immobilising the truncated second at least partially double stranded oligonucleotide of step d), the unreacted second at least partially double-stranded oligonucleotide and/or the uncut first ligation product via the modification to a surface; f) optionally repeating steps a) to e), whereby the elongated first at least partially double-stranded oligonucleotide of step d) serves as the first at least partially double-stranded oligonucleotide in step a). | 2009-12-03 |
20090298134 | Method to increase the yield and improve purification of products from transaminase reactions - A process for producing high yields of enantioselective amino acids and chiral amines by reacting a keto acid or ketone and an amino acid donor in the presence of a transaminase biocatalyst to produce a keto acid by-product and an amino acid or amine product. Further reacting the keto acid by-product with a peroxide to increase the yield of additional amino acid or amine product. | 2009-12-03 |
20090298135 | Method for fermentative production of L-methionine - A microorganism strain suitable for fermentative production of L-methionine and preparable from a starting strain, which comprises increased activity of a yjeH gene product or of a gene product of a yjeH homolog, compared to the starting strain. | 2009-12-03 |
20090298136 | Methionine producing recombinant microorganisms - This invention relates to methionine producing recombinant microorganisms. Specifically, this invention relates to recombinant strains of | 2009-12-03 |
20090298137 | MICROORGANISM AND PROCESS FOR THE PREPARATION OF L-METHIONINE - The present invention relates to microorganisms and processes for the efficient preparation of L-amino acids such as L-methionine. In particular, the present invention relates to microorganisms and processes in which the formation and/or accumulation of homolanthionine in the methionine pathway is reduced and/or prevented. | 2009-12-03 |
20090298138 | MICROORGANISM PRODUCING L-THREONINE HAVING AN INACTIVATED LYSR GENE, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING L-THREONINE USING THE MICROORGANISM - Provided are a microorganism having an inactivated lysR gene in its chromosome and can produce L-threonine, a method of producing the microorganism, and a method d of producing L-threonine using the method. The microorganism can produce L-threonine with a high yield. | 2009-12-03 |
20090298139 | Method for Polymer Synthesis Using Microfluidic Enzymatic Cascade - The present invention discloses a method for producing polymers in a microscale device. The system utilizes a symmetrically branched system of microchannels interconnecting a plurality of loading decks and re-action chambers. The fluid flow is manipulated by the placement of capillary check valves, mixing areas, and microcomb filters. The system provides for cascading enzymatic biosynthesis pathways wherein any variety of enzymes and reactants can be introduced into the system to produce a final product. | 2009-12-03 |
20090298140 | Solid State Matrix, Process of Preparation Thereof, and Process of Preparation of Theaflavins - The present invention relates to a process for the development of a highly efficient solid state matrix by the activation of acrylate based polymer resin having specialized functional groups with 1,1-Carboxyl diimidazole for immobilizing biologically active macromeloecules such as oxidases, in particular plant oxidases and the most preferred being tea polyphenol oxidase through indirect covalent bonding/cross linking on such activated polymer resin support, are thermally stable, gives very high number of turnovers in vitro (“n” times) with tea substrate forming exclusive product Theaflavins without any loss of biological activity and leaving the product remaining in vitro with adherence to matrix rendering the matrix safe towards product poisoning and subsequent partial or complete loss of biological activity of the matrix bound enzyme system and thus well adapted to and well suited biorectors based on such systems. It is unique with respect to its recyclability or otherwise uneconimical tea substrates such as seed and flower substrates into theaflavins both with respect to crude substrate or purified ones. | 2009-12-03 |
20090298141 | Continuous Chemical Proceses in Centrifugal Contact Separators - The invention relates to the use of a centrifugal contact-separator for carrying out a non-radioactive reaction in a liquid-liquid emulsion formed from two immiscible liquids. The invention also relates to a process for carrying out a reaction in a centrifugal contact-separator, and to a process for carrying out a catalytic reaction in a centrifugal contact-separator. An example of a process for carrying out a reaction, comprising the following steps: i) continuously introducing a liquid phase A and a liquid phase B into at least one first centrifugal contact separator, where in liquid phases A and B are immiscible and wherein phase A and/or phase B comprise at least one reactant ii) mixing phase A and phase B thereby allowing an emulsion to be formed iii) applying a centrifugal force that allows phase separation of the emulsion, such that phases A′ and B′ are obtained; iv) optionally, recovering a reaction product from at least one or the phases A′ and B′. | 2009-12-03 |
20090298142 | METHOD FOR PRODUCING A USEFUL SUBSTANCE BY USE OF AN IMMOBILIZED ENZYME - The present invention provides a method for producing a useful substance by supplying, to a fixed-bed reactor packed with an immobilized enzyme, a liquid mixture containing two liquid phases, in which the two liquid phases are allowed to flow in an identical, parallel direction, which method employs a fixed-bed reactor equipped with an insertion unit or tubes, so as to form a plurality of lumens in the fixed-bed reactor, each lumen having a cross section of a circular shape with a diameter of 100 mm or less or having a polygonal shape with a diagonal line of 100 mm or less, wherein the lumens are packed with an immobilized enzyme and the liquid mixture is supplied therethrough. In a reaction performed by passing a reaction mixture exhibiting two liquid phases through a fixed-bed reactor equipped with an immobilized enzyme, overall flow of the reaction liquid is made uniform, to thereby facilitate production of a useful substance in an efficient manner. | 2009-12-03 |
20090298143 | SECRETION OF FATTY ACIDS BY PHOTOSYNTHETIC MICROORGANISMS - Recombinant photosynthetic microorganisms that convert inorganic carbon to secreted fatty acids are described. Methods to recover the secreted fatty acids from the culture medium without the need for cell harvesting are also described. | 2009-12-03 |
20090298144 | METHODS OF MANUFACTURING DERIVATIVES OF BETA-HYDROXYCARBOXYLIC ACIDS - Preparation of derivatives of β-hydroxycarboxylic acid, including β-hydroxycarboxylic acid esters, α,β-unsaturated carboxylic acid, esters of α,β-unsaturated carboxylic acid, and alkoxy derivatives. | 2009-12-03 |
20090298145 | Acid-resistance endoglucanase and the use of thereof - The present teachings relate to an acid-resistant endoglucanase, which is a protein exhibiting excellent endoglucanase activity under acidic conditions. The present teachings provide a protein having the amino acid sequence set forth in SEQ ID NO: 2, a protein having an amino acid sequence with one or more amino acid modifications in the amino acid sequence set forth in SEQ ID NO: 2 and having endoglucanase activity, or a protein having an amino acid sequence with at least 75% homology to the amino acid sequence set forth in SEQ ID NO: 2 and having endoglucanase activity. | 2009-12-03 |
20090298146 | Method of Producing Astaxanthin or Metabolic Product Thereof by Using Carotenoid Ketolase and Carotenoid Hydroxylase Genes - To provide a microorganism or a plant transformed with a β-ionone ring-4-ketolase gene and/or β-ionone ring-3-hydroxylase gene derived from | 2009-12-03 |
20090298147 | Method of Making (+)- Sitophilure - (+)-Sitophilure, the aggregation pheromone of the pests rice weevil and maize weevil, is synthesized in high yield and diastereomeric excess by contacting 4-methyl-3,5heptadione with a reduced nicotinamide cofactor and a ketoreductase enzyme capable of catalyzing the reduction of 4-methyl-3,5-heptadione to produce (4R,5S)-5-hydroxy-4-methyl-3-heptanone to the substantial exclusion of other diastereomers. | 2009-12-03 |
20090298148 | REGIO- AND ENANTIOSELECTIVE ALKANE HYDROXYLATION WITH MODIFIED CYTOCHROME P450 - Cytochrome P450 BM-3 from | 2009-12-03 |
20090298149 | Sulfite Pretreatment For Biorefining Biomass - The present invention relates to a method using sulfite pretreatment to overcome recalcitrance of lignocellulose (SPORL). More specifically, it relates to a sulfite-based chemical process for pretreating biomass in solutions to reduce access barriers of enzymes to the lignocellulose, resulting in efficient conversion through enzymatic saccharification. | 2009-12-03 |
20090298150 | PRODUCTION OF SQUALENE USING YEAST - Provided herein compositions and methods for producing isoprenoids, including squalene. In certain aspects and embodiments provided are genetically altered yeast and uses therefore. In some aspects and embodiments, the genetically altered yeast produce isoprenoids, preferably squalene. The genetically altered yeast may have alterations in the expression or activity of enzymes involved in squalene production. for example, acetyl-CoA carboxylase (or “ACCase”), HMG-CoA reductase, squalene epoxidase, and squalene synthase. One or more genes of a genetically altered yeast may be modified by gene repair oligonucleobases. Also are provided methods of producing squalene using a genetically altered yeast. The invention also provides squalene produced by genetically altered yeast. | 2009-12-03 |
20090298151 | HYDROGEN PRODUCING MICROORGANISM USEFUL FOR ENERGY GENERATION FROM DIVERSE CARBONACEOUS FEEDSTOCK - The disclosed invention relates to an isolated hydrogen gas producing microorganism, termed | 2009-12-03 |
20090298152 | PROCESS FOR THE SIMULTANEOUS REMEDIATION AND PRODUCTION OF FUEL FROM FRACTIONALIZED WASTE AND VIRGIN MATERIALS THROUGH THE USE OF COMBINATIVE BIOREACTOR AND CATALYTIC METHODOLOGY - A process for the production of fuel or biodiesel, and use of the process to fuel an on-site engine. The process includes introducing an effluent stream into a first vessel, the effluent stream containing solids and at least one of vegetable oil and petroleum oil. The process includes heating the effluent to lower its viscosity in the first vessel, separating at least some of the solids from the heated effluent to form a reactant stream, introducing the reactant stream to a bioreactor, introducing at least one remediation agent into the bioreactor, heating the reactor contents to a reaction temperature, and allowing sufficient time to pass such that the reactant stream yields a fuel product. | 2009-12-03 |
20090298153 | METHOD FOR ULTRASONIC CELL REMOVAL - The present invention provides a method for treating cell culture vessels including multi-layer cell culture vessels with ultrasonic energy to dissociate cells growing on surfaces of cell culture vessels. | 2009-12-03 |
20090298154 | Conjugated biological molecules and their preparation - Novel biologically active compounds of the general formula (I) in which one of X and X′ represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X′ represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X′ and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z | 2009-12-03 |
20090298155 | Epigenetic Regulatory Complex for Control of Gene Expression - An epigenetic regulatory polypeptide complex comprises at least a first domain having site-specific DNA binding activity and at least a second domain having an arginine methyltransferase activity, wherein the second domain is capable of methylating an arginine residue located in the tail region of a histone H2A. The complex is able to regulate gene expression in cells, particularly in mammalian stem cells by controlling the methylation of R3 in the tail regions of histones H2A and H4. The complex is exemplified by a polypeptide complex comprising the DNA binding activity of Blimpi and the arginine methyltransferase activity of Prmt5. | 2009-12-03 |
20090298156 | Thymidine Kinase Mutants and Fusion Proteins Having Thymidine Kinase and Guanylate Kinase Activities - The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Such mutations include amino acid substitutions within a Q substrate binding domain which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within a further aspect, fusion proteins are provided which have both guanylate kinase and thymidine kinase biological properties. Also provided are vectors suitable for expressing such DNA molecules, as well as methods for utilizing such vectors. | 2009-12-03 |
20090298157 | HEPARAN SULFATE GLYCOSAMINOGLYCAN LYASE AND USES THEREOF - The invention provides recombinant | 2009-12-03 |
20090298158 | ADIABATIC COMPACTION OF ALGAE BIOMASS FOR EXTRACTION OF BIOFUEL - A technique for extracting biofuel from algae biomass using high velocity adiabatic impact compaction, comprising impacting a quantity of algae biomass with a power ram at a controlled velocity to deliver an impulse of sufficient magnitude to disrupt the outer cell wall structure. | 2009-12-03 |
20090298159 | Method for producing biodiesel from an alga - A method is provided to produce biodiesel from algae using a two-stage, autotrophic and heterotrophic cultivations of | 2009-12-03 |
20090298160 | Reaction vessel and reaction controller - The invention relates to a reaction vessel and a reaction controller, wherein temperature control of a liquid stored within the vessel can be performed with a high accuracy and faithful responsiveness. The reaction container and the reaction controller comprise one or a plurality of reaction chambers in which liquid is storable, and a wall that surrounds the reaction chamber, and the entirety or a part of the wall is formed by a temperature raising and lowering body that can raise or lower the temperature thereof according to a signal from an instructing part provided outside. | 2009-12-03 |
20090298161 | Surface Treatment - A biosensor comprising surface treated with a method for producing a monolayer of molecules on a surface, the method comprising loading a stamp with seed molecules, transferring seed molecules from the stamp to the surface, wherein transferring comprises transferring a fraction of the seed molecules loaded on the stamp to the surface and adsorbing the seed molecules to the stamp and adsorbing the seed molecules to the surface, the adsorption of the seed molecules to the stamp being stronger than the adsorption of the seed molecules to the surface, self-completing amplification of the seed molecules via an amplifying reaction to produce the monolayer on a flat surface, wherein self-completing amplification comprises producing a homogeneous area, wherein the homogeneous area comprises a monolayer of molecules on the surface, and wherein the monolayer of molecules on the surface has no diffusive component that can relocate and destroy amplification accuracy. | 2009-12-03 |
20090298162 | BIOSENSORS FOR MONITORING RECEPTOR-MEDIATED G-PROTEIN ACTIVATION - The present invention relates to novel biosensors that are based on bioluminescence resonance energy transfer (BRET). These biosensors may be used to monitor rapid interaction and conformational changes within G protein-coupled receptor/G protein complexes and, in this way, reflect the activation status of the receptor. Advantageously, the biosensors may be used as a highly sensitive and quantitative assay for the identification of ligands (agonists, antagonists, inverse agonists, partial agonists, etc.) targeting G protein-coupled receptors (GPCRs) as well as for the analysis of the activation status of these receptors. Moreover, multiplexing different biosensors within receptors/G protein complexes allows for mapping ligand textures. Additionally, the biosensors permit the direct, real-time examination of interactions between receptors and G protein in their natural environment, the living cell. | 2009-12-03 |
20090298163 | MULTILAYER CELL CULTURE VESSELS - A multilayered cell culture apparatus for the culturing of cells is disclosed. The cell culture apparatus includes a unitary flask body including a rigid upper and lower surface, connected by side walls. The cell growth apparatus comprises multiple cell growth chambers stacked in vertical alignment and orientation within the unitary flask body. The stacked chambers are held in position by unitary connecting columns that run through each cell growth chamber and terminate at the rigid upper and lower surfaces of the apparatus. The cell growth chambers are separated by tracheal spaces that allow air from the external environment to contact the cell growth surface of each individual cell growth chamber. | 2009-12-03 |
20090298164 | ASSEMBLY OF CELL CULTURE VESSELS - A cell culture apparatus includes a cell culture chamber formed by a first major surface, an opposing second major surface spaced apart from the first major surface, and a first side wall around the first chamber and extending between the first and second major surfaces. A portion of the first sidewall proximate the first major surface comprises an infrared absorbent material, and a portion the first sidewall proximate the second major surface is formed from substantially non-infrared absorbent material. The first major surface is formed by a gas permeable polymeric film that is impermeable to cell culture liquid. | 2009-12-03 |
20090298165 | Process for removing selenium from air or water - A process for removing selenium from air or water can use proteins naturally found in bacteria able to live in selenium rich environments to capture and/or reduce the selenium to an insoluble form that can be captured. | 2009-12-03 |
20090298166 | CELL CULTURE APPARATUS HAVING VARIABLE TOPOGRAPHY - A cell culture apparatus includes a substrate having formed therein a micro-pillared well array. The micro-pillared well array includes a plurality of micro-pillared wells. Each micro-pillared structure includes a plurality of spaced-apart micro-pillars having distal ends shaped to form a well. The well is suitable for cell culture. | 2009-12-03 |
20090298167 | INTERLEUKIN-21 RECEPTOR BINDING PROTEINS - The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders. | 2009-12-03 |
20090298168 | Method of genetically altering and producing allergy free cats - A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, Fel d I. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct. The phenotype of the transgenic cat is transmissible to its offspring. | 2009-12-03 |
20090298169 | Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems - The invention relates to methods that allow for the efficient differentiation to form pancreatic endoderm cells from pluripotent stem cells such as human embryonic stem cells and definitive endoderm cells. The invention is directly applicable to the ultimate generation of pancreatic beta cells that could be used as part of a therapy to treat or even cure diabetes. Additionally, the present invention may be used to generate liver endoderm cells from human embryonic stem cells and definite endoderm cells as well. This invention relates to a method for generating definitive endoderm and pancreatic endoderm cells from stem cells, preferably human embryonic stem cells using defined media in the absence of feeder cells. A simply two step procedure to provide pancreatic endoderm cells from embryonic stem cells represents further embodiments of the present invention. | 2009-12-03 |
20090298170 | HEPATOCYTE LINEAGE CELLS - Disclosed herein are methods for producing liver precursor cells as well as hepatocyte cells form pluripotent and/or multipotent cells. Also disclosed herein are methods of enriching isolating and/or purifying liver precursor cells and/or hepatocyte cells. Further disclosed are compositions comprising cell cultures and cell populations that are enriched for liver precursor cells or hepatocyte cells. | 2009-12-03 |
20090298171 | Method and Device for Treating or Selecting Cells - The present invention is directed to a method of treating cells by co-culturing them with activated fibroblasts in order to regulate the growth and/or status of the cells. Fibroblasts are activated by culturing the cells under conditions that induce the cells to adhere to each other to form multicellular aggregates or spheroids. The present invention also provides a device for selecting cells from cell samples, such as bone marrow aspirate, the device comprises said multicellular aggregates. | 2009-12-03 |
20090298172 | Histological specimen treatment apparatus and method - Method and apparatus for processing tissue specimens against decomposition, putrefaction and autolysis which use a simple three step procedure in a single vessel or container. First, the specimens are saturated with a solvent mixture of a ketone and a hydrocarbon, e.g., an Acetone/Hexane or an Acetone/Xylene mixture, to dissolve lipids and other cellular solutes. The container is then flooded with melted Paraffin. In a last step, the solvent mixture is vaporized and evacuated from the container, allowing the melted Paraffin to replace the vaporized solvent and impregnate the specimens. Raw, i.e., non-processed and non-burred specimens up to 5 mm thick can be processed in about 60 minutes. A solvent regenerator distills the evacuated solvent; and converts vent waste gases into carbon dioxide and water through a thermocatalytic oxidizer. | 2009-12-03 |
20090298173 | Method of preparing cell for bone tissue formation and application of cell for bone tissue formation - It is intended to provide a method of efficiently and stably preparing a cell having a bone tissue formation ability by a simple operation. Further, it is intended to provide a method of preparing a composition for bone tissue formation with high safety and an excellent therapeutic effect by a simple operation. The cell for bone tissue formation is obtained by (1) culturing bone marrow after isolating it from a living body, diluting it at a predetermined dilution ratio and inoculating it to a culture vessel, (2) culturing the remaining adhesive cells after removing floating components, (3) inducing differentiation of proliferated cells to bone cells and (4) recovering the cells. The thus obtained cells, a thrombin solution, platelet-rich plasma and air are mixed at a predetermined mixing ratio (based on volume) in the presence of calcium ions and the mixture is gelled, whereby a gelled composition is obtained. | 2009-12-03 |